![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Drug Research
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced it has launched...
News
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332;...
Press Releases
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII),...
Clinical Trials
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial,...
Clinical Trials
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC294640) in hospitalized...
News
Glenmark completes PMS study of Covid-19 drug Favipiravir
Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India....
News
EUA for Lilly’s bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
The U.S. FDAhas expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read